Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217724 · ClinicalTrials.gov registry record · NA
Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer
A NA study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT00217724 is a NA study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT00217724, a NA study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Nutritional supplements, such as glutamine, may prevent side effects caused by chemotherapy. PURPOSE: This randomized clinical trial is studying glutamine to see how well it works compared to placebo in preventing myalgia and/or arthralgia in patients who are receiving paclitaxel for cancer.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1999-07 |
| Est. Completion | 2009-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217724
The ClinicalTrials.gov registry entry for NCT00217724 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00217724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00217724 about?
NCT00217724 is a clinical study titled "Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Nutritional supplements, such as glutamine, may prevent side effects caused by chemotherapy. PURPOSE: This randomized ...
What is the current status of trial NCT00217724?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 1999-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00217724?
The interventions under investigation include: placebo (OTHER), glutamine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00217724?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.